Multimodality Treatment Outcome in Adult Patients with Head and Neck Rhabdomyosarcoma
The Laryngoscope · 2025
DOI: 10.1002/lary.31968 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, 2025. Verfasst von Tian Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Eye, Ear, Nose & Throat Hospital of Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Rhabdomyosarcoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Natural Science Foundation grants of Chongqing.
Abstract (Originalsprache)
Objective(s) Head and neck rhabdomyosarcoma (HNRMS) is a rare malignant tumor in adults. No standard treatment for adults with HNRMS currently exists.
Methods
A retrospective study of 72 newly diagnosed consecutive adult patients with HNRMS was conducted at one institution between November 2010 and April 2023. The log‐rank tests were used to compare the differences in survival between treatment groups, and overall survival (OS), local recurrence‐free survival (LRFS), progression‐free survival (PFS), and distant metastasis‐free survival (DMFS) were calculated using the Kaplan–Meier method. We used restricted cubic spline models fitted for Cox proportional hazards models to determine the association between chemotherapy cycles/radiotherapy dose and mortality.
Results
The 2‐year OS, PFS, LRFS, and DMFS rates for the entire cohort were 51.0%, 39.2%, 44.3%, and 47.3%, respectively. Radiotherapy significantly improved the OS ( p < 0.01), PFS ( p < 0.01), LRFS ( p < 0.01), and DMFS ( p < 0.01). Surgery had no effect on OS (49.3% vs. 53.0%, p = 0.62), PFS (36.9% vs. 41.8%, p = 0.31), LRFS (41.6% vs. 47.4%, p = 0.27), or DMFS (44.4% vs. 50.2%, p = 0.43). The restricted cubic spline showed that eight (HR = 1.002, 95% CI: 0.996–1.007) cycles of chemotherapy and 62.5Gy radiation therapy resulted in the lowest mortality.
Conclusion
For HNRMS, eight cycles of chemotherapy and 62.5Gy of radiation might be sufficient. Poor response to chemotherapy predicted an extreme worse outcome. Surgery played a limited role in the treatment. Level of Evidence 3 Laryngoscope , 135:2022–2029, 2025
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Eye, Ear, Nose & Throat Hospital of Fudan University, Shanghai, China.
- Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
- Chongqing University Cancer Hospital and Chongqing Cancer Institute and Chongqing Cancer Hospital, Chongqing, China.
- Department of Otorhinolaryngology, Jinshan Hospital Affiliated to Fudan University, Shanghai, China.
- Department of Oncology, 920th Hospital of Joint Logistics Support Force, Kunming, China.
ORCID-Profile: Tian Wang, Xinmao Song
Förderung
- Natural Science Foundation grants of Chongqing
Zitieren
APA
Wang, T., Huang, C., Wang, J., Tang, T., Li, Q., Li, Y., & Song, X. (2025). Multimodality Treatment Outcome in Adult Patients with Head and Neck Rhabdomyosarcoma. The Laryngoscope. https://doi.org/10.1002/lary.31968
Vancouver
Wang T, Huang C, Wang J, Tang T, Li Q, Li Y, et al. Multimodality Treatment Outcome in Adult Patients with Head and Neck Rhabdomyosarcoma. The Laryngoscope. 2025. doi:10.1002/lary.31968
BibTeX
@article{Wang2025,
author = {Wang, Tian and Huang, Chuang and Wang, Jie and Tang, Tianci and Li, Qiang and Li, Yi and Song, Xinmao},
title = {Multimodality Treatment Outcome in Adult Patients with Head and Neck Rhabdomyosarcoma},
journal = {The Laryngoscope},
year = {2025},
doi = {10.1002/lary.31968}
}
EUVIMED